Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 22, 2017
Pharmacy Choice - Pharmaceutical News - cCAM Biotherapeutics Secures FDA OK to Initiate Phase 1 Trial for CM- 24 [Professional Services Close - Up] - November 22, 2017

Pharmacy News Article

 1/18/15 - cCAM Biotherapeutics Secures FDA OK to Initiate Phase 1 Trial for CM- 24 [Professional Services Close - Up]

cCAM Biotherapeutics said it has received approval form the US Food and Drug Administration to commence a Phase 1 trial for CM-24, a first-in-class immunomodulatory monoclonal antibody (mAb) for the treatment of various types of cancers. The study is expected to commence during the first quarter of 2015.

According to a company release, CM-24 is directed against CEACAM1, a novel immune checkpoint protein that is expressed on activated effector lymphocytes and a variety of cancer cells. CEACAM1 belongs to the Human CEA protein family, and preclinical data show that inhibition of CEACAM1-CEACAM1 homophilic interactions by CM-24 leads to enhanced activation of tumor specific immune cells.

Pini Orbach, Ph.D., Chairman of the Board, cCAM Biotherapeutics, stated: "Antibodies blocking immune checkpoints are emerging as a breakthrough treatment that can, in some cases, lead to a cure even in advanced stage cancer. Unfortunately, a large proportion of patients do not respond to these drugs. Currently approved immune checkpoint inhibitors are based on protein targets from the B7-CD28 family, and therefore novel immune checkpoint targets from different protein families may increase the response rate to treatment. cCAM is developing a first-in-class cancer immunotherapy that is directed against a novel immune checkpoint from the CEA protein family using a different mechanism of action than the current immune checkpoint inhibitors on the market. We therefore hope that our drug will increase the percentage of cancer patients responding to treatment. This is a very exciting era in oncology, and we look forward to launching the first-in-human clinical trial with CM-24."

Professor Antoni Ribas, M.D., Ph.D., Department of Medicine, Hematology/Oncology at the Jonsson Comprehensive Cancer Center, UCLA, commented, "We are impressed by the preclinical data to date, and are excited to take part in this trial, assessing the safety and tolerability of a new, first-in-class immune checkpoint inhibitor. Unlike current immune checkpoints isolated to date, CEACAM1 acts both as the receptor and the ligand. CEACAM1 on a tumor cell binds to another CEACAM1 molecule on an immune cell in order to inhibit an immune attack on the tumor. Therefore, it is possible that the CM- 24 antibodies blocking the activity of CEACAM1 will have a strong effect in inhibiting this particular immune-modulating pathway."

More information:

ccam-bio.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))



(c) 2015 ProQuest Information and Learning Company; All Rights Reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Nov 29: Influenza 2017-2018: An Update on Prevention and Treatment
Nov 30: School is Out! Life is in Session: The Importance of Professional Development in Pharmacy
Dec 01: Anticoagulants: The Rapidly Changing Landscape
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415